{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T09:33:02Z","timestamp":1750930382272,"version":"3.37.3"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100023103","name":"DHHS","doi-asserted-by":"publisher","award":["75N91019D00024"],"award-info":[{"award-number":["75N91019D00024"]}],"id":[{"id":"10.13039\/100023103","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.nano.2024.102780","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T04:01:26Z","timestamp":1724385686000},"page":"102780","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["In vitro assessment of nanomedicines' propensity to cause palmar-plantar erythrodysesthesia: A Doxil vs. doxorubicin case study"],"prefix":"10.1016","volume":"62","author":[{"given":"Edward","family":"Cedrone","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abbas","family":"Ishaq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Grabarnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elijah","family":"Edmondson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Skoczen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry W.","family":"Neun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Freer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siannah","family":"Shuttleworth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisbet","family":"Sviland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Dickinson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marina A.","family":"Dobrovolskaia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2024.102780_bb0005","first-page":"494","article-title":"The hand-foot syndrome\u2014a frequent secondary manifestation in antineoplastic chemotherapy","volume":"16","author":"Janusch","year":"2006","journal-title":"Eur J Dermatol"},{"key":"10.1016\/j.nano.2024.102780_bb0010","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.ejon.2006.10.004","article-title":"Palmar-plantar erythrodysesthesia (PPE): a literature review with commentary on experience in a cancer centre","volume":"11","author":"Webster-Gandy","year":"2007","journal-title":"Eur J Oncol Nurs"},{"key":"10.1016\/j.nano.2024.102780_bb0015","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/j.ejca.2008.01.028","article-title":"Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts","volume":"44","author":"von Moos","year":"2008","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.nano.2024.102780_bb0020","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1136\/ejhpharm-2020-002311","article-title":"Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: a literature review of pharmaceutical and clinical aspects","volume":"28","author":"Zhu","year":"2020","journal-title":"Eur J Hosp Pharm"},{"key":"10.1016\/j.nano.2024.102780_bb0025","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ygyno.2009.04.007","article-title":"Predisposing risk factors for palmar-plantar erythrodysesthesia when using liposomal doxorubicin to treat recurrent ovarian cancer","volume":"114","author":"Tanyi","year":"2009","journal-title":"Gynecol Oncol"},{"year":"2023","series-title":"Doxorubicin, StatPearls [Internet]","author":"Johnson-Arbor","key":"10.1016\/j.nano.2024.102780_bb0030"},{"key":"10.1016\/j.nano.2024.102780_bb0035","doi-asserted-by":"crossref","first-page":"5095","DOI":"10.1038\/s41598-024-55185-4","article-title":"A real-world analysis of FDA Adverse Event Reporting System (FAERS) events for liposomal and conventional doxorubicins","volume":"14","author":"Su","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.nano.2024.102780_bb0040","series-title":"Nanomedicines: Design, Delivery, and Detection","first-page":"315","article-title":"Doxil\u00ae \u2013 the first FDA-approved nano-drug: from basics via CMC, cell culture and animal studies to clinical use","author":"Barenholz","year":"2016"},{"key":"10.1016\/j.nano.2024.102780_bb0045","first-page":"261","article-title":"FDA strategies to prevent and respond to drug shortages: finding a better way to predict and prevent company closures","volume":"38","author":"Barlas","year":"2013","journal-title":"Pharm Ther"},{"year":"2011","series-title":"Executive Order 13588 - Reducing Prescription Drug Shortages, White House, Washington DC","author":"Obama","key":"10.1016\/j.nano.2024.102780_bb0050"},{"key":"10.1016\/j.nano.2024.102780_bb0055","series-title":"FDA Approves Generic Version of Doxil; Expected to Help Resolve Shortage","first-page":"25","volume":"35","year":"2013"},{"year":"2024","series-title":"Liposomal Doxorubicin Market: Liposomal Doxorubicin Market Analysis by Branded and Generic From 2024 to 2034","author":"Ghosh","key":"10.1016\/j.nano.2024.102780_bb0060"},{"key":"10.1016\/j.nano.2024.102780_bb0065","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1021\/acsptsci.0c00011","article-title":"Distinguishing pharmacokinetics of marketed nanomedicine formulations using a stable isotope tracer assay","volume":"3","author":"Skoczen","year":"2020","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.nano.2024.102780_bb0070","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/wics.1310","article-title":"Bioavailability and bioequivalence in drug development","volume":"6","author":"Chow","year":"2014","journal-title":"Wiley Interdiscip Rev Comput Stat"},{"key":"10.1016\/j.nano.2024.102780_bb0075","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrd818","article-title":"Bioequivalence and the immunogenicity of biopharmaceuticals","volume":"1","author":"Schellekens","year":"2002","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.nano.2024.102780_bb0080","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1056\/NEJM198509123131101","article-title":"An in vitro predictive test for graft versus host disease in patients with genotypic HLA-identical bone marrow transplants","volume":"313","author":"Vogelsang","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.nano.2024.102780_bb0085","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1038\/nm0402-410","article-title":"In situ dissection of the graft-versus-host activities of cytotoxic T cells specific for minor histocompatibility antigens","volume":"8","author":"Dickinson","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.nano.2024.102780_bb0090","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jcp.55.2.127","article-title":"The detection of apoptosis in a human in vitro skin explant assay for graft versus host reactions","volume":"55","author":"Jarvis","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.1016\/j.nano.2024.102780_bb0095","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1097\/TP.0b013e318212c833","article-title":"The involvement of epithelial Fas in a human model of graft versus host disease","volume":"91","author":"Ruffin","year":"2011","journal-title":"Transplantation"},{"key":"10.1016\/j.nano.2024.102780_bb0100","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1097\/TP.0b013e3181ac14ce","article-title":"Regulatory T-cell suppression of CD8+ T-cell-mediated graft-versus-host reaction requires their presence during priming","volume":"88","author":"Wang","year":"2009","journal-title":"Transplantation"},{"key":"10.1016\/j.nano.2024.102780_bb0105","first-page":"323","article-title":"Skin explant culture as a model for cutaneous graft-versus-host disease in humans","volume":"3","author":"Dickinson","year":"1988","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nano.2024.102780_bb0110","first-page":"65","article-title":"Cytokine involvement in predicting clinical graft-versus-host disease in allogeneic bone marrow transplant recipients","volume":"13","author":"Dickinson","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nano.2024.102780_bb0115","first-page":"105","article-title":"An in vitro predictive test for clinical graft-versus-host disease in allogeneic bone marrow transplant recipients","volume":"5","author":"Sviland","year":"1990","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.nano.2024.102780_bb0120","first-page":"367","article-title":"Histopathology of graft-vs.-host reaction (GvHR) in human recipients of marrow from HL-A-matched sibling donors","volume":"6","author":"Lerner","year":"1974","journal-title":"Transplant Proc"},{"key":"10.1016\/j.nano.2024.102780_bb0125","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1002\/jat.3197","article-title":"An in vitro human skin test for assessing sensitization potential","volume":"36","author":"Ahmed","year":"2016","journal-title":"J Appl Toxicol"},{"key":"10.1016\/j.nano.2024.102780_bb0130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.taap.2019.02.005","article-title":"Evaluation of a human in vitro skin test for predicting drug hypersensitivity reactions","volume":"369","author":"Ahmed","year":"2019","journal-title":"Toxicol Appl Pharmacol"},{"issue":"5","key":"10.1016\/j.nano.2024.102780_bb0135","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3390\/toxics12050332","article-title":"A human skin explant test as a novel in vitro assay for the de-tection of skin sensitization to aggregated monoclonal antibodies","volume":"12","author":"Martins-Ribeiro","year":"2024","journal-title":"Toxics"},{"issue":"6","key":"10.1016\/j.nano.2024.102780_bb0140","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3390\/toxics12060401","article-title":"An in vitro human skin test for predicting skin sensitisation and adverse immune reactions to biologics","volume":"12","author":"Ahmed","year":"2024","journal-title":"Toxics"},{"key":"10.1016\/j.nano.2024.102780_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.jid.2022.11.024","article-title":"TNF-\u03b1\u2013mediated keratinocyte expression and release of matrix metalloproteinase 9: putative mechanism of pathogenesis in Stevens\u2013Johnson Syndrome\/toxic epidermal necrolysis","volume":"143","author":"Olsson-Brown","year":"2023","journal-title":"J Invest Dermatol"},{"key":"10.1016\/j.nano.2024.102780_bb0150","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1097\/00007890-197410000-00001","article-title":"Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors","volume":"18","author":"Glucksberg","year":"1974","journal-title":"Transplantation"},{"key":"10.1016\/j.nano.2024.102780_bb0155","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1111\/j.1600-6143.2008.02243.x","article-title":"The Banff 2007 working classification of skin-containing composite tissue allograft pathology","volume":"8","author":"Cendales","year":"2008","journal-title":"Am J Transplant"},{"key":"10.1016\/j.nano.2024.102780_bb0160","doi-asserted-by":"crossref","first-page":"3678","DOI":"10.1038\/s41596-020-0393-6","article-title":"Use of human peripheral blood mononuclear cells to define immunological properties of nucleic acid nanoparticles","volume":"15","author":"Dobrovolskaia","year":"2020","journal-title":"Nat Protoc"},{"key":"10.1016\/j.nano.2024.102780_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.984252","article-title":"Lessons learned from immunological characterization of nanomaterials at the Nanotechnology Characterization Laboratory","volume":"13","author":"Dobrovolskaia","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.nano.2024.102780_bb0170","first-page":"10","article-title":"In vitro cell toxicity and intracellular uptake of doxorubicin exposed as a solution or liposomes: implications for treatment of hepatocellular carcinoma","author":"Kullenberg","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.nano.2024.102780_bb0175","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/10717540601036831","article-title":"Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab\u2019 fragments of an anti-CD74 antibody","volume":"14","author":"Lundberg","year":"2007","journal-title":"Drug Deliv"},{"key":"10.1016\/j.nano.2024.102780_bb0180","doi-asserted-by":"crossref","first-page":"949","DOI":"10.2147\/IJN.S72590","article-title":"In vitro cytotoxicity analysis of doxorubicin-loaded\/superparamagnetic iron oxide colloidal nanoassemblies on MCF7 and NIH3T3 cell lines","volume":"10","author":"Tomankova","year":"2015","journal-title":"Int J Nanomedicine"},{"key":"10.1016\/j.nano.2024.102780_bb0185","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1039\/c2ib20117h","article-title":"Common pitfalls in nanotechnology: lessons learned from NCI\u2019s Nanotechnology Characterization Laboratory","volume":"5","author":"Crist","year":"2013","journal-title":"Integr Biol (Camb)"},{"key":"10.1016\/j.nano.2024.102780_bb0190","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1093\/toxsci\/kfm169","article-title":"Nanotechnology safety concerns revisited","volume":"101","author":"Stern","year":"2008","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.nano.2024.102780_bb0195","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1159\/000098701","article-title":"Human skin penetration of sunscreen nanoparticles: in-vitro assessment of a novel micronized zinc oxide formulation","volume":"20","author":"Cross","year":"2007","journal-title":"Skin Pharmacol Physiol"},{"key":"10.1016\/j.nano.2024.102780_bb0200","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/toxsci\/kfj122","article-title":"Penetration of intact skin by quantum dots with diverse physicochemical properties","volume":"91","author":"Ryman-Rasmussen","year":"2006","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.nano.2024.102780_bb0205","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1093\/toxsci\/kfq041","article-title":"Lack of significant dermal penetration of titanium dioxide from sunscreen formulations containing nano- and submicron-size TiO2 particles","volume":"115","author":"Sadrieh","year":"2010","journal-title":"Toxicol Sci"},{"key":"10.1016\/j.nano.2024.102780_bb0210","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1093\/annonc\/mdh097","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien","year":"2004","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nano.2024.102780_bb0215","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"10.1016\/j.nano.2024.102780_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114079","article-title":"To PEGylate or not to PEGylate: immunological properties of nanomedicine\u2019s most popular component, polyethylene glycol and its alternatives","volume":"180","author":"Shi","year":"2022","journal-title":"Adv Drug Deliv Rev"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963424000492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963424000492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,24]],"date-time":"2024-10-24T07:26:22Z","timestamp":1729754782000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963424000492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":44,"alternative-id":["S1549963424000492"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2024.102780","relation":{},"ISSN":["1549-9634"],"issn-type":[{"type":"print","value":"1549-9634"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In vitro assessment of nanomedicines' propensity to cause palmar-plantar erythrodysesthesia: A Doxil vs. doxorubicin case study","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2024.102780","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102780"}}